Normocalcemic primary hyperparathyroidism;Hiperparatiroidismo normocalcêmico primário

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 54, Issue 2, 2010, Pages 106-109

  Bilezikian, John P ^a   Silverberg, Shonni J ^a  

^a Columbia University ^*  (United States)

Author keywords

Bone disease; Calcium; Normocalcemic hyperparathyroidism

Indexed keywords

EID: 77952685740     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302010000200004     Document Type: Review

References (17)

1. Lepage R, Roy L, Brossard JH, Rousseau L, Dorais C, Lazure C, et al. A non (1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin Chem. 44:805-9.
2. D'Amour P, Brossard J-H, Rousseau L, et al. Structure of non-(1- 84) PTH fragments secreted by parathyroid glands in primary and secondary hyperparathyroidism. Kidney Int. 2005;68:998-1007.
3. Gao P, Scheibel S, D'Amour P, John MR, Rao SD, Schmidt-Gayk H, et al. Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84. Implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res. 2001;16:605-14.
4. Silverberg SJ, Brown I, LoGerfo P, Gao P, Cantor T, Bilezikian JP. Clinical utility of an immunoradiometric assay for whole PTH (1-84) in primary hyperparathyroidism. J Clin Endocrinol Metab. 2003;88:4725-30.
5. Maruani G, Hertig A, Paillard M, Houillier P. Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone. J Clin Endocrinol Metab. 2003;88:4641-8.
6. Silverberg SJ, Bilezikian JP. "Incipient" primary hyperparathyroidism: a "forme fruste" of an old disease. J Clin Endocrinol Metab. 2003;88:5348-52.
7. Wills MR, Pak CY, Hammond WG, Bartter FC. Normocalcemic primary hyperparathyroidism. Am J Med. 1967;47:384-91.
8. Monchik JM, Gorgun E. Normocalcemic hyperparathyroidism in patients with osteoporosis. Surgery. 2004;136:1242-6.
9. Heaney RP. The vitamin D requirement in health and disease. J Steroid Biochem Molec Biol. 2005;97:13-9.
10. Holick MF. Vitamin D deficiency. N Eng J Med. 2007;357:266-81
11. Lundgren E, Hagstrom EG, Lundin J, Winnerback MB, Roos J, Ljunghall S, et al. Primary hyperparathyroidism revisited in menopausal women with serum calcium in the upper normal range at population based screening 8 yrs ago. World J Surg. 2002;26:931-6.
12. Tordjman KM, Greenman Y, Osher E, Shenkerman G, Sern N. Characterization of normocalcemic primary hyperparathyroidism. Am J Med. 2004;117:861-3.
13. Rao DS, Wilson RJ, Kleerekoper M, Parfitt AM. Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism: evidence for biphasic disease course. J Clin Endocrinol Metab. 1988;67:1294-8.
14. Lowe H, McMahon DJ, Rubin MR, Bilezikian JP, Silverberg SJ. Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab. 2007;92:3001-5.
15. Bilezikian JP, Potts JT Jr, El-Hajj Fuleihan G, Kleerekoper M, Neer R, et al. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Bone Min Res. 2002;17(suppl 2):N2-11. J Clin Endocrinol Metab. 2002;87:5353-61.
16. National Institutes of Health: Consensus Development Conference Statement on Primary Hyperparathyroidism. J Bone Miner Res. 1991;6:S9-13.
17. Bilezikian JP, Khan A, Potts JT Jr. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab. 2009;94:335-9.